SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing intense volatility as investors closely monitor geopolitical escalations in the Middle East, specifically threats surrounding the Strait of Hormuz and potential impacts on global energy supply chains. Market participants are actively debating the sustainability of current tech valuations and discussing whether the recent pullbacks represent a strategic buying opportunity or the beginning of a deeper market correction driven by macroeconomic uncertainty.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is facing a sharp sell-off as a combination of a surging dollar, rising interest rate expectations, and broader liquidity concerns drives investors to exit precious metal positions. The community is actively debating whether this is a temporary shakeout that offers a buying opportunity for long-term holders or a more systemic shift that challenges gold's status as a traditional safe-haven asset during times of geopolitical tension.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is currently trending as investors grapple with extreme market volatility driven by escalating geopolitical tensions in the Middle East and the uncertainty surrounding impending policy deadlines. The community is sharply divided, with intense debate focused on whether these conditions signal an imminent market collapse or a temporary shakeout that will ultimately favor opportunistic buyers.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing significant volatility as market participants react to intensifying geopolitical tensions in the Middle East and the company's involvement in broader national political discourse. Investors and community members are actively debating the potential economic impact of these escalations, with sentiment heavily divided between those betting on stock recovery and those expressing concerns over the firm's long-term stability.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is facing intense downward pressure driven by a combination of broader market volatility and a persistent short-seller report from Muddy Waters, which has triggered aggressive trading from both retail bulls and institutional bears. The community remains deeply divided, with many long-term investors pointing to CEO Anthony Noto’s recent insider buying as a signal of fundamental strength, while bears emphasize the ongoing uncertainty surrounding the firm’s accounting practices and macro-economic headwinds.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla stock is facing downward pressure amid significant market volatility, fueled by investor skepticism regarding the timing of upcoming projects like the 'Terafab' chip factory and broader concerns over global geopolitical stability. The community remains deeply polarized, with many traders closely monitoring support levels while others debate the impact of high-profile leadership announcements against ongoing concerns about the company's valuation and delivery timelines.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is facing downward pressure as investors express skepticism over the company's massive capital expenditures toward AI infrastructure and the recent decision to scale back its metaverse initiatives. Community sentiment is deeply divided, with some traders bracing for further volatility due to technical chart patterns and layoff rumors, while long-term investors maintain conviction in the stock's underlying fundamentals and growth potential.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is trending as investors weigh the impact of rising geopolitical tensions and inflationary pressures on the junior gold miners sector. Community sentiment remains split between bullish bets on gold as a hedge against systemic risk and bearish warnings about the volatility and leverage inherent in the instrument.

Meet Soyjak. Soyjak, a portmanteau of "soy" and "wojak", is a variation of Wojak that combines Wojak-style illustrations with additional features to allude to a soy boy, such as a gaping "cuckface" with an excited expression, glasses, stubble, and a balding head.  Launched stealth with presale, zero taxes, LP burnt and contract renounced.  Soyjak is more than a token it's a movement to embrace the underdog in all of us and transform setbacks into comebacks!  Soyjak.party, (or just "The party") is an imageboard dedicated to the creation, posting, and sharing of soyjaks. As the site has grown, its expanded to encompass many other topics as well. Please read the rules before posting. Serving 9,462,739 posts!

Soyjak

The SOY symbol is facing heightened volatility and intense investor debate as market participants weigh geopolitical instability, ongoing tariff threats, and the potential impact of upcoming domestic policy shifts. Discussions are heavily focused on navigating macroeconomic pressures, with traders actively monitoring technical chart patterns and shifting institutional sentiment amidst the broader market turbulence.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a major breakthrough in EUV light source technology that could significantly boost chip production efficiency by 2030, alongside anticipation for upcoming earnings. The community remains focused on the company's long-term dominance as an essential 'pick and shovel' play for the ongoing AI infrastructure build-out.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.&nbsp;</li><li>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year.</li><li>Earlier this week, Sarepta also said that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its DMD gene therapy Elevidys.</li></ul>Sarepta Therapeutics (SRPT) said on Thursday that it intends to make certain submissions to the U.S. Food and Drug Administration regarding two of its Duchenne muscular dystrophy therapies by the end of April, in a move applauded by Wall Street.Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, with the help of data from a confirmatory late-stage study.The company said that the FDA has confirmed that data from the trial can be submitted as part of the application. However, the adequacy of the data to support conversion to traditional approval will be a matter of review, the company said.<h2 class="st-heading-2">Analyst Takeaway</h2>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year. The analyst added that it also signals positive FDA feedback during a meeting, pointing to potential sNDA approval.The firm reiterated an ‘Outperform’ rating on Sarepta with a price target of $37 on the shares.<h2 class="st-heading-2">About Vyondys And Amondys</h2>Vyondys 53 and Amondys 45 are both FDA-approved, weekly intravenous antisense oligonucleotide therapies from Sarepta for Duchenne muscular dystrophy (DMD), a severe, progressive genetic disorder primarily affecting young boys, characterized by muscle degeneration. Both therapies now have an accelerated approval.While Accelerated Approval (AA) allows faster market access for drugs treating serious conditions, based on surrogate endpoints that likely predict clinical benefit, Traditional Approval requires direct evidence of clinical benefit. Accelerated approval requires post-marketing confirmatory trials to prove clinical efficacy to prevent the approval from being withdrawn.With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.<h2 class="st-heading-2">Sarepta’s Update For Elevidys</h2>Earlier this week, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">said</a> that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SRPT stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 79% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 

Equity

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 


<ul class="summary-bullets"><li>Guggenheim also raised its price target on CytomX Therapeutics to $15 from $10 and kept a ‘Buy’ rating on the shares.</li><li>Jefferies sees as much as a $5 billion market opportunity for Varseta-M.&nbsp;</li><li>According to data from Koyfin, all the nine analysts covering CTMX rate it ‘Buy’ or higher.</li></ul>Multiple analysts raised their price target on shares of CytomX Therapeutics Inc (CTMX) on Wednesday on the heels of the company announcing positive early-stage trial data from lead asset Varseta-M.One of the analysts raised the price target on the stock to $18, representing a potential upside of about 230% from the stock’s last closing price on Tuesday.<h2 class="st-heading-2">Trial Data Stokes Optimism</h2>Earlier this week, the company announced positive data for Varseta-M in late-line metastatic colorectal cancer. The company said about 32% of patients responded to the treatment at the higher dose and 20% at the lower dose, with the disease kept from worsening for a median of around 7 months in both groups. The drug helped control the cancer in more than 80% of patients, and most side effects were considered manageable, the company said.CytomX said it plans to engage with the U.S. Food and Drug Administration (FDA) mid-year to align on a potential registrational study. The company is also testing Varseta-M in combination with Bevacizumab, a therapy that blocks the blood supply to tumors.Multiple analysts hiked their price targets on the stock following the update, with Jefferies and Guggenheim being the latest to join the parade.<h2 class="st-heading-2">Fresh Analyst Take</h2>Jefferies raised the firm's price target on CytomX Therapeutics to $16 from $8 and kept a ‘Buy’ rating on the shares following the "impressive" Phase 1 Varseta-M data update in late-line metastatic colorectal cancer (mCRC). The firm sees a buying opportunity with "a rare ADC asset" capable of generating about a $1 billion-plus opportunity in third-line and later mCRC alone, with potential to about $5 billion-plus as it moves into first and second-line, the analyst told investors.Guggenheim also raised its price target on CytomX Therapeutics to $15 from $10 and kept a ‘Buy’ rating on the shares. The firm, which is updating its model and estimates following the company's recent disclosure, said the data for both the 8.6 and 10mg/kg dose levels exceeds the benchmarks for current standard of care options by "a wide margin," which justifies increasing its view of the odds of success to 60% from 30%, previously.According to data from Koyfin, all the nine analysts covering CTMX rate it ‘Buy’ or higher. The average 12-month price target on the stock is $11.67, representing a potential upside of over 150% from current trading levels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CTMX stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CTMX">CTMX</a> has risen 671% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/eric-trump-says-abtc-has-more-bitcoin-than-glxy/cZ371mWRIgD">Eric Trump Says ABTC Has More Bitcoin Than GLXY – Stock Still Falls Amid Bitcoin’s Decline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CytomX Therapeutics logo is displayed on the screen of a tablet.

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside

Jefferies raised its price target to $18, representing a potential upside of about 230% from the stock’s last closing price on Tuesday.

The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM

IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.

<ul class="summary-bullets"><li>Stocktwits activity surged after the NCCN update, with message volumes jumping over 300% in 24 hours.</li><li>Retail traders flagged bullish calls on revenue growth and “generational wealth” in response to the update.</li><li>The update comes as ImmunityBio pursues FDA label expansion for papillary disease.</li></ul>Shares of ImmunityBio, Inc. (IBRX) rose nearly 1% in overnight trading&nbsp;heading into Tuesday, with retail traders spotting a “recommended” status for the company's bladder cancer therapy on the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 33 leading cancer centers.Investors on social media are already framing the development&nbsp;as a catalyst for&nbsp;Anktiva's real-world adoption, citing potential gains in prescriptions and insurance coverage.<h2 class="st-heading-2">Retail Buzz Surges After NCCN Update</h2>On Stocktwits, activity around ImmunityBio surged following the NCCN filing, with message volumes jumping more than 300% over the past 24 hours, while its watcher base has climbed 41% over the past three months.Meanwhile, sentiment toward the SPDR S&amp;P Biotech ETF (XBI) was ‘bullish,’ with message volume surging over 250% in the past 24 hours and the ETF up nearly 2% so far this year.<figure class="image"><img src="https://news.stocktwits-cdn.com/xbi_ss_png_0d39d2b2db.webp" alt="xbi ss.png" width="971" height="144"><figcaption>XBI sentiment and message volume as of March 17 | Source: Stocktwits</figcaption></figure>Stocktwits independently confirmed that the latest NCCN guidelines released Monday list Anktiva plus BCG as an “other recommended” treatment option for patients with certain types of high-risk bladder cancer, including both CIS and papillary-only disease.One retail watcher<a href="https://stocktwits.com/Regener8/message/647704512">&nbsp;struck</a> a bullish tone, saying, “Profitability is guaranteed since the NCCN news just increased our market by 6-10 times in the US!” The user went on to outline a revenue ramp scenario, adding, “Add triple our current sales and we’d be at breakeven… at 8 times an increase we break a billion in sales… we get to $2 billion in annual revenue.”&nbsp;&nbsp;Others echoed the conviction, though with a more tactical lens. “Not enough folks know about NCCN approval… time to load again!!!” another user<a href="https://stocktwits.com/YeboGogo/message/647703032">&nbsp;said</a>, adding that the development could represent “generational wealth creation” for investors willing to stay invested through near-term moves.At the same time, some users<a href="https://stocktwits.com/h8888l/message/647702742">&nbsp;suggested</a> the impact may take time to reflect in price action fully. “The market will react, but retail investors will not see it instantly.”&nbsp;<h2 class="st-heading-2">Retail Traders Flag Adoption Upside For Anktiva</h2>Retail commentary focused heavily on how the update could influence real-world use of Anktiva. “If NCCN updates ANKTIVA for papillary: insurers will reimburse immediately, oncologists will start prescribing,” one user said.Another<a href="https://stocktwits.com/EMC99/message/647701843">&nbsp;user</a> pointed to the clinical update, noting that the latest NCCN guidelines now list Anktiva as a Category 2B option for BCG-unresponsive high-risk bladder cancer, including papillary-only disease, adding that while this means it is considered “useful in certain circumstances,” it is still part of the standard treatment framework used by oncologists.The same user added that expansion into papillary-only patients is significant, as those cases were previously limited to chemotherapy, trials, or other intravesical options, arguing that inclusion could lead to “more doctors prescribing” and “insurance coverage improving dramatically.”Another user pointed to the strength of the recommendation itself, saying the papillary-only segment “seems to imply” a Category 2A rating and calling that outcome “golden,” while noting that making this explicit would be key.<h2 class="st-heading-2">What The NCCN Listing Shows</h2>A review of the latest NCCN Guidelines shows that Anktiva, which is available under the generic name Nogapendekin alfa (inbakicept-pmln), when used with standard BCG, is now listed as an “other recommended” treatment option for patients with high-risk bladder cancer that has not responded to BCG. This includes both patients with carcinoma in situ (CIS) and those with papillary-only disease, effectively expanding its use into a broader group of patients.In the guidelines, Anktiva appears alongside other bladder-sparing treatments such as chemotherapy-based options and gene therapy, while surgery and clinical trials remain the top “preferred” choices.Some therapies, like Pembrolizumab (Keytruda), an immunotherapy developed by Merck, are listed for use in certain situations, while single-drug chemotherapy is included as a lower-evidence option in some cases. The update places Anktiva within the standard set of treatments doctors can consider across both major forms of this disease, even as the company continues to seek a formal FDA label expansion.<h2 class="st-heading-2">Off-Label Path And FDA Catalyst In Focus</h2><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> fell over 2% on Monday to end at $8.21, with shares nearly tripling over the past year. The retail narrative builds on developments from<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-down-this-week-ceo-outlines-3-reasons-bull-case-intact/cZdwCPyRIaO">&nbsp;last week</a>, when ImmunityBio said physicians could begin prescribing Anktiva for papillary bladder cancer ahead of formal FDA approval if the therapy were included in treatment guidelines.CEO Richard Adcock said last week that the company had submitted supporting data to the NCCN, adding that inclusion could allow prescribing based on clinical guidance while the company works toward regulatory expansion.The company has also<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">&nbsp;resubmitted</a> its supplemental biologics license application to the U.S. Food and Drug Administration (FDA) for papillary disease, with a potential update expected in the coming weeks.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins

Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement.

Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave

IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.

<ul class="summary-bullets"><li>Polaryx Therapeutics went public via a direct listing on Feb. 2.</li><li>The biotech firm is developing treatments for lysosomal storage disorders (LSDs).</li><li>Stocktwits sentiment for PLYX shifted to ‘extremely bullish’ after the stock rally.</li></ul>Shares of Polaryx Therapeutics (PLYX), a newly listed clinical-stage biotech firm, surged 70% on Tuesday,&nbsp;its best session on record, spurring increased interest from retail traders on Stocktwits. The micro-cap stock surged 29% on Monday.<h2 class="st-heading-2">Biotech Stocks Drawing Interest</h2>Polaryx is focused on rare neurodegenerative diseases and is currently testing its PLX-200 treatment aimed at treating lysosomal storage disorders (LSDs), genetic diseases where the body can’t break down certain molecules, causing harmful buildup inside cells.Biotech names have been catching investors' eyes as they seek shelter from the market turbulence triggered by the US-Israel conflict with Iran. Drug stocks have emerged as a go-to safe haven amid all the geopolitical uncertainty this year: the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF</a> (XBI) has gained over 4% this year while the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust</a> (SPY) and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust Series 1</a> (QQQ) index funds (which track the benchmark U.S. indices) have shed about 1%.Polaryx’s pipeline includes four drug candidates, namely, PLX-200, PLX-100, PLX-300, and PLX-400 for LSDs. The last three are still in the preclinical stage.<h2 class="st-heading-2">Recent Updates From PLYX</h2>The recent uptrend in the stock was likely triggered as investors took note of the company’s research advances. The company&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nasdaq.com/articles/polaryx-initiate-soteria-phase-2-basket-trial-1h2026-stock?utm_source=chatgpt.com">announced</a> on Feb. 17 that it was moving forward with its phase-2 trial evaluating PLX-200 in four lysosomal storage disorders (LSDs) after receiving a “safe-to-proceed” letter from the Food and Drug Administration in October.Last week, Maxim initiated coverage on the PLYX with a ‘Buy’ rating and $10 price target, which implies a 66% upside to the stock’s last close. The firm said it views PLX-200 as a differentiated offering, given its oral formulation and potential to address a broad spectrum of LSDs by targeting shared disease pathways.<h2 class="st-heading-2">Retail’s View On PLYX</h2>On Stocktwits, retail sentiment for PLYX shifted to ‘extremely bullish’ as of early Wednesday, from ‘bullish’ the prior day, amid ‘extremely high’ message volume. The watcher count for&nbsp;<a href="https://stocktwits.com/symbol/PLYX">PLYX</a> on the platform increased nearly 50% over the past 24 hours.Several users&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.stocktwits.com/NorthernMonkey1/message/647157001">said</a> they would be watching the stock in the coming days.“$PLYX development stage biotech that traders tend to position in ahead of pipeline progress updates. These setups usually need sustained volume to get momentum going,” one trader&nbsp;<a href="https://stocktwits.com/topstockalerts/message/647155307">said</a>, explaining the prevailing view.About 25 million PLYX shares exchanged hands on Tuesday, about nine times the stock’s average trading volume, according to Stocktwits data.<h2 class="st-heading-2">Stock Widely Down Since Listing</h2>Polaryx’s recent gains come&nbsp;as a relief, as the stock slid sharply after its direct listing on the Nasdaq on Feb. 2. Shares currently trade at about one-tenth of their opening price of $45.00 that day.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-shuts-up-the-bears-as-ceo-touts-faster-cheaper-ai-wall-street-is-totally-buying-it/cZdANc5RIJT">Oracle Shuts Up The Bears As CEO Touts 'Faster, Cheaper' AI: Wall Street Is Totally Buying It</a>

Traders work on the floor of the New York Stock Exchange.

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest?

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.

PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.


<ul class="summary-bullets"><li>Mizuho believes this leadership change is "constructive for uniQure."</li><li>H.C. Wainwright also opined earlier on Tuesday that the departure of Prasad at the end of April "reshapes the regulatory calculus" for uniQure's AMT-130.</li><li>FDA commissioner Marty Makary confirmed on Friday that Center for Biologics Evaluation and Research chief Prasad would leave in April.</li></ul>Mizuho on Tuesday upgraded uniQure (QURE) to ‘Outperform’ from ‘Neutral’, in light of Friday's "unexpected" announcement that Dr. Vinay Prasad will depart the U.S. Food and Drug Administration (FDA).Prasad’s exit just days after a highly public dispute with uniQure, "appears to signal an administration-level desire to restore greater regulatory flexibility in rare disease development," Mizuho said.The firm believes this leadership change is "constructive for uniQure," potentially reopening a path to an application based on the existing data or a late-stage trial leveraging natural history controls, the analyst told investors.H.C. Wainwright also opined earlier on Tuesday that the departure of Prasad at the end of April "reshapes the regulatory calculus" for uniQure's AMT-130. H.C. Wainwright has "continued conviction" in AMT-130's existing dataset and uniQure's broader pipeline, it said, while adding that QURE shares are "poised for a value inflection."<h2 class="st-heading-2">Prasad’s Exit</h2>FDA commissioner Marty Makary <a href="https://stocktwits.com/news-articles/markets/equity/fda-vaccine-chief-vinay-prasad-to-exit-agency-in-april-report/cZdLgVkRI4a">confirmed</a> on Friday that Center for Biologics Evaluation and Research chief Prasad would leave in April. Prasad had sparred with uniQure recently, going up against the company’s gene therapy AMT-130 for ⁠Huntington's disease.The agency has recommended that the company conduct a new controversial study, including a controversial sham surgery control group, for approval of the therapy after disagreeing with other study data submitted.uniQure raised ethical concerns about such a trial design, arguing that it could expose patients to surgical risks without therapeutic benefit.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>QURE stock closed 1.5% higher on Tuesday and edged up 1% after hours.On Stocktwits, retail sentiment around QURE stock stayed within ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is up 56% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mgnx-closes-up-on-wall-street-optimism-for-experimental-cancer-therapies/cZdY5gORI7q">MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit

Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease development. 

<ul><li>H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.</li><li>The firm stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.</li><li>Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating, citing Prasad’s departure for its optimism.</li></ul>uniQure NV stock continued to draw retail buzz after analysts at H.C. Wainwright noted on Tuesday that the shares are poised for a value inflection following the reported departure of a key U.S. Food and Drug Administration (FDA) official.According to TheFly, analysts at H.C. Wainwright reiterated their ‘Buy’ rating and a $70 price target for the stock, implying a potential upside of nearly 289% from Monday’s closing price.<a href="https://stocktwits.com/symbol/QURE">uniQure shares</a> were up nearly 7% in Tuesday’s pre-market trade after a 26% surge on Monday.<h2 class="st-heading-2">Why Is HC Wainwright Bullish?</h2>H.C. Wainwright stated that the departure of Vinay Prasad, the head of the FDA’s division of vaccines and gene therapies at the end of April, bodes well for uniQure, stating that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.H.C. Wainwright stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.Prasad is reportedly leaving the agency next month to return to academia.Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating. The firm cited Prasad’s departure as the reason for its price target hike.Earlier this month, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">FDA&nbsp;</a>said it does not agree that uniQure’s Phase I/II data for AMT-130 are sufficient to serve as theprimary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around uniQure trended in the ‘bullish’ territory at the time of writing.One user stated that this is the “gene therapy trade reset traders waited for.”<stembedurl>https://stocktwits.com/TradeThePool/message/647080386</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 25% year-to-date, but up 45% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bill-ackman-pershing-square-files-for-ipo-after-a-delay-of-more-than-a-year/cZdoYmJRIeU">Bill Ackman’s Pershing Square Files For IPO After A Delay Of More Than A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

<ul class="summary-bullets"><li>UniQure’s AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain.</li><li>The FDA recently said that data from uniQure’s Phase I/II trials were not sufficient and recommended a new randomized Phase III study.</li><li>RBC Capital estimates a 50% chance of eventual approval as Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130.</li></ul>Shares of uniQure N.V. (QURE) surged more than 20% on Monday, following upgrades from Wall Street firms, citing a potentially improving regulatory outlook for its Huntington’s disease therapy.Wells Fargo upgraded the company to ‘Overweight’ from ‘Equal Weight’ and sharply raised its price target to $60 from $15, according to The Fly. This implies a 243% potential rise from its current price of around $17.5.<h2 class="st-heading-2">Vinay Prasad’s Reported Departure In Spotlight</h2>Wells Fargo said the outlook for uniQure’s experimental gene therapy AMT-130 could improve following reports that Vinay Prasad will leave the U.S. Food and Drug Administration (FDA) next month. Prasad, who serves as both the Chief Medical and Scientific Officer and the Director of the Center for Biologics Evaluation and Research at the FDA, is set to leave next month, according to a Bloomberg report on Friday.Wells Fargo also noted that strong criticism from the media and the Huntington’s disease community over the FDA’s call for a new Phase 3 trial highlights stakeholder support for the therapy. That backing could strengthen the drug’s chances during review, approval, and commercialization.AMT-130 is a gene therapy to reduce levels of the Huntingtin protein in the brain. It uses a virus to deliver genetic instructions that help lower the protein. The treatment is administered directly into the striatum, an area of the brain heavily affected by Huntington’s disease, through a surgical procedure.Separately, RBC Capital Markets upgraded uniQure to ‘Outperform’ from ‘Sector Perform’ and raised its price target to $35 from $11. The firm said Prasad’s exit could reopen a more balanced discussion at the FDA about the risk-benefit profile of AMT-130, estimating about a 50% chance of eventual approval.<h2 class="st-heading-2">FDA Seeks New Randomized Study</h2>The upgrades come after regulatory uncertainty weighed on the company earlier this year. The FDA recently said that data from uniQure’s Phase I/II trials were insufficient to support a marketing application and recommended that the company conduct a new randomized Phase III study, including a controversial sham surgery control group.uniQure has raised ethical concerns about such a trial design, arguing that it could expose patients to surgical risks without therapeutic benefit. The company plans to request another meeting with the FDA in the second quarter of 2026 to discuss potential study designs.Despite the regulatory debate, AMT-130 has shown promising early data. In an earlier study, patients receiving a high dose of the gene therapy experienced about a 75% slower rate of disease progression after three years, along with a slower decline in both motor function and cognitive ability.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp rally, retail sentiment for <a href="https://stocktwits.com/symbol/QURE">QURE</a> on Stocktwits turned ‘bullish’ from ‘extremely bullish’ a day earlier, amid ‘extremely high’ message volumes.One user expects the stock to surge to $150 if the company receives the FDA approval.<stembedurl>https://stocktwits.com/ChineseTakeeout/message/646975511</stembedurl>Another user weighed the options present for short sellers and long-term investors.<stembedurl>https://stocktwits.com/sepsis74/message/646972082</stembedurl>The stock has declined nearly 28% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/saudi-arabia-begins-slashing-oil-production-tpet-batl-indo-shares-continue-to-draw-retail-buzz/cZdVlsWRIIj">Saudi Arabia Begins Slashing Oil Production – TPET, BATL, INDO Stocks Continue To Draw Retail Buzz</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

<ul class="summary-bullets"><li>Following discussions with the FDA beginning in January 2026, ImmunityBio resubmitted its supplemental BLA for papillary-only NMIBC after providing additional data requested by the agency, including updated efficacy results.</li><li>The filing includes long-term follow-up data and study results for Anktiva plus Bacillus Calmette-Guérin in patients with bladder cancer and papillary tumors, published in The Journal of Urology.</li><li>ImmunityBio plans to present clinical data supporting the Saudi Food and Drug Authority approval of the chemotherapy-free regimen of Anktiva plus checkpoint inhibitors.</li></ul>ImmunityBio Inc. (IBRX) on Monday announced that it has resubmitted the supplemental biologics license application (BLA) to the U.S. Food and Drug Administration for Anktiva.ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio shares</a> were down more than 1% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Filing Includes Long-Term Follow-Up Data</h2>Following discussions with the FDA beginning in January 2026, ImmunityBio resubmitted its supplemental BLA for papillary-only NMIBC after providing additional data requested by the agency, including updated efficacy results.The filing includes long-term follow-up data, and safety and efficacy results for Anktiva plus BCG in BCG-unresponsive NMIBC with papillary tumors have been published in The Journal of Urology."As far back as 2007, IL-15 was identified by leading scientific and medical organizations, including the NCI, NIH, FDA, AACR, and ASH, as the number one-ranked immunotherapy molecule with the potential to cure cancer," said Dr. Patrick Soon-Shiong, ImmunityBio’s founder and Executive Chairman.<h2 class="st-heading-2">ImmunityBio Plans To Present Data Supporting Saudi Approval</h2>ImmunityBio plans to present clinical data supporting the Saudi Food and Drug Authority (SFDA) approval of the chemotherapy-free regimen of Anktiva plus checkpoint inhibitors, which showed nearly twice the median overall survival compared with historical outcomes with docetaxel chemotherapy.The company said it will also continue discussions with the FDA and other global regulators on potential treatment options for patients with second-line and later metastatic non-small cell lung cancer (NSCLC) who have exhausted current standards of care, including checkpoint inhibitors.<h2 class="st-heading-2">ImmunityBio’s Partnership To Expand Anktiva Access</h2>In March, the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-partnership-to-expand-access-to-anktiva-across-30-countries/cZRkGiwR4D5">partnered</a> with Accord Healthcare to expand access to Anktiva across 30 countries. It also established an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe.Under the agreement, Accord will deploy more than 100 sales, medical, and marketing professionals to support the adoption of Anktiva across the United Kingdom, the European Union, Norway, Iceland, and Liechtenstein.Soon-Shiong said the company aims to broaden access to Anktiva by completing a randomized trial in patients with BCG-naïve disease.This includes individuals with non-muscle invasive bladder cancer (NMIBC) who have never received Bacillus Calmette-Guérin (BCG) immunotherapy or whose cancer recurs more than 24 months after prior BCG treatment.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> is up 332% year-to-date and 185% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-rlmd-stock-soaring-today/cZdVSq1RIIW">RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XBI News

XBISPDR S&P Biotech ETF